These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22393002)

  • 41. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
    Speiser DE; Schwarz K; Baumgaertner P; Manolova V; Devevre E; Sterry W; Walden P; Zippelius A; Conzett KB; Senti G; Voelter V; Cerottini JP; Guggisberg D; Willers J; Geldhof C; Romero P; Kündig T; Knuth A; Dummer R; Trefzer U; Bachmann MF
    J Immunother; 2010 Oct; 33(8):848-58. PubMed ID: 20842051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD4
    Imai N; Tawara I; Yamane M; Muraoka D; Shiku H; Ikeda H
    Cancer Sci; 2020 Jun; 111(6):1958-1968. PubMed ID: 32304127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IL-2 during in vitro priming promotes subsequent engraftment and successful adoptive tumor immunotherapy by persistent memory phenotypic CD8(+) T cells.
    Bathe OF; Dalyot-Herman N; Malek TR
    J Immunol; 2001 Oct; 167(8):4511-7. PubMed ID: 11591778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro.
    Pham Minh N; Murata S; Kitamura N; Ueki T; Kojima M; Miyake T; Takebayashi K; Kodama H; Mekata E; Tani M
    Int J Cancer; 2018 Jun; 142(11):2335-2343. PubMed ID: 29313971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.
    Chapuis AG; Lee SM; Thompson JA; Roberts IM; Margolin KA; Bhatia S; Sloan HL; Lai I; Wagener F; Shibuya K; Cao J; Wolchok JD; Greenberg PD; Yee C
    J Exp Med; 2016 Jun; 213(7):1133-9. PubMed ID: 27242164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.
    Jazirehi AR; Baritaki S; Koya RC; Bonavida B; Economou JS
    Cancer Res; 2011 Feb; 71(4):1406-17. PubMed ID: 21159666
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
    Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
    Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
    J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NIH3T3 Directs Memory-Fated CTL Programming and Represses High Expression of PD-1 on Antitumor CTLs.
    Qin Y; Lee Y; Seo J; Kim T; Shin JH; Park SH
    Front Immunol; 2019; 10():761. PubMed ID: 31031760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
    Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
    Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.
    Neeson P; Shin A; Tainton KM; Guru P; Prince HM; Harrison SJ; Peinert S; Smyth MJ; Trapani JA; Kershaw MH; Darcy PK; Ritchie DS
    Gene Ther; 2010 Sep; 17(9):1105-16. PubMed ID: 20428216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations.
    Yamshchikov G; Thompson L; Ross WG; Galavotti H; Aquila W; Deacon D; Caldwell J; Patterson JW; Hunt DF; Slingluff CL
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):909s-916s. PubMed ID: 11300491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.
    D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P
    Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells.
    Liu Z; Liu JQ; Talebian F; Wu LC; Li S; Bai XF
    Eur J Immunol; 2013 Feb; 43(2):468-79. PubMed ID: 23225163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.
    Verdegaal EM; Visser M; Ramwadhdoebé TH; van der Minne CE; van Steijn JA; Kapiteijn E; Haanen JB; van der Burg SH; Nortier JW; Osanto S
    Cancer Immunol Immunother; 2011 Jul; 60(7):953-63. PubMed ID: 21431917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
    Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
    J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor Infiltrating Effector Memory Antigen-Specific CD8
    Principe N; Kidman J; Goh S; Tilsed CM; Fisher SA; Fear VS; Forbes CA; Zemek RM; Chopra A; Watson M; Dick IM; Boon L; Holt RA; Lake RA; Nowak AK; Lesterhuis WJ; McDonnell AM; Chee J
    Front Immunol; 2020; 11():584423. PubMed ID: 33262762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.